Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.80.

Several research firms have weighed in on RGLS. Canaccord Genuity Group raised their target price on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Tuesday. Finally, Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RGLS. CVI Holdings LLC acquired a new stake in shares of Regulus Therapeutics during the first quarter worth $4,050,000. Vanguard Group Inc. boosted its stake in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares during the last quarter. NEA Management Company LLC purchased a new stake in Regulus Therapeutics in the 1st quarter valued at about $18,627,000. RA Capital Management L.P. acquired a new position in shares of Regulus Therapeutics during the 1st quarter valued at about $18,000,000. Finally, Opaleye Management Inc. purchased a new position in shares of Regulus Therapeutics during the 1st quarter worth about $490,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Price Performance

Shares of NASDAQ:RGLS opened at $1.55 on Friday. The firm has a market capitalization of $101.47 million, a price-to-earnings ratio of -1.06 and a beta of 1.62. The business’s 50 day simple moving average is $1.61 and its 200-day simple moving average is $2.00. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). On average, equities analysts anticipate that Regulus Therapeutics will post -0.8 earnings per share for the current year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.